

Rinowash



Nebuliser for the upper airways,
ideal for treating rhinitis, rhino-sinusitis,
nasal polyposis, adenoiditis
and tubo-tympanitis
using drugs or physiological solutions.

The RINOWASH kit is clinically tested with and without drug.
Studies published on the most important specialized magazines
are available on request.



Rinowash enhances deposition in the upper airways as it produces particles greater than 10 microns in diameter.

Characteristics

Effective:

By producing particles size >10 microns, it acts exclusively on the UPPER AIRWAYS.

Convenient:

Compatible with all pneumatic aerosol devices.

Rapid:

Atomizes 5 ml solution in one minute.

Versatile:

Can be used from a very early age, with no contraindications.

A INTERNAL CHAMBER

holds the fluid to nebulize.

B EXTERNAL CHAMBER

collects the return fluid.

C ERGONOMIC GRIP

with a flow control button



Rinowash is designed for treating the upper airways in patients of any age. It features a special patented internal valve that prevents overpressure in the nasal cavities and the risk of barotrauma.



As from 1st June 2009 Markos Mefar has become
Air Liquide Medical Systems S.p.A.

AIR LIQUIDE MEDICAL SYSTEMS S.p.A.
Via dei Prati 62 - 25073 Bovezzo (Brescia)
Tel. +39 030 20159.11
Fax +39 030 2098329

www.airliquidemedicalsystems.it
CE₀₀₅₁ www.airliquidemedicalsystems.com

Air Liquide's Healthcare business supplies medical gases & equipment to hospitals, medical services to patients at home and is active in the fight against nosocomial infections. Its 7,800 employees serve 5,000 hospitals and 300,000 patients, on five continents. Air Liquide is the world leader in gases for industry, health and the environment.